As if the market reaction to the war in Ukraine were not enough, global stock markets have been smashed in an apparent in a hissy fit at rising US inflation and the possibility of sharply higher interest rates. Action today on the ASX was reminiscent of the market meltdown that Read more…
Melbourne based Dimerix Ltd perfectly fits our description of an Undiscovered Biotech. With its ~AUD$78M market cap and 3 x phase 3 clinical trials ongoing, there’s compelling reasons to take a look at this company. Background In 2004 Dimerix Bioscience was spun out of the University of Western Australia and the Read more…
In massive news overnight, the Australian government has revealed that it’s reached an in-principle agreement with US company, Moderna, to produce mRNA vaccines in Australia Unsurprisingly, Melbourne has won the hotly contested race to be Australia’s home of mRNA production. It’s understood that the NSW government lobbed in a financially Read more…
The ASX reacted with surprise to the historic news that IDT Australia has become the first company to produce an mRNA vaccine in Australia. The shares closed the day, up 40%. Less surprised were long term shareholders who have been awaiting this development for several months. Australia now joins Read more…
IDT Australia -September update It takes a special kind of investor (some would say crazy) to invest in biotech companies. Extreme patience is required as the timelines for progress are often measured in years. In dispersed with this can be brief periods where the ground can shift under you Read more…
The waiting game Nothing happens quickly in the world of biotech, and from an investor point of view this can be the toughest part. For shareholders in Melbourne based stem cell company, Mesoblast, the waiting game has been excruciating. As the world ground to a halt due to the Read more…
IDT Australia – July update IDT are not terribly forthcoming with regular updates to markets but we can begin to piece together various sources to picture what the near future may look like. The submissions deadline for the Australian governments approach-to-market (ATM) to onshore mRNA manufacturing passed on July Read more…
PolyNovo – Changing lives. It’s often said that need is the mother of invention and it couldn’t be truer for NovoSorb BTM (Biodegradable Temporizing Matrix), the lead product of Melbourne based biotech, PolyNovo. Following the 2002 Bali terrorist bombings, many survivors were airlifted to Australia for treatment, often with Read more…
Circadian Technologies It was back in June 2007 when I bought a small parcel of shares in a Melbourne based company called Circadian Technologies after watching them, on and off, for several months. Originally functioning as a commercial vehicle for outstanding, diverse biomedical research, the company successfully launched Read more…
In last night’s budget handed down by Australia’s federal government it was announced that funding has been allocated to create from scratch a capability to manufacture mRNA vaccines on Australian soil. For those of us paying attention will know that IDT Australia had earlier made a bold pitch to the Read more…